title: Patient Capital's Q3 2025 Top Contributors And Detractors
source: SeekingAlpha
date: 2025-10-16
url: https://finnhub.io/api/news?id=effc725c36190630494a3b93c4e0a6164289e5d4a806797e4ec199957234840b
Precigen Inc. was a top contributor to the portfolio following the early approval of Papziemos for the treatment of recurrent respiratory papillomatosis in early August.
